Well-controlled HIV doesn't affect heart metabolism, function

January 26, 2012 By Jim Dryden, Washington University School of Medicine in St. Louis
PET images from patients with blood sugar and lipid problems and other metabolic complications (top) show the heart has difficulty converting glucose to energy. In those without metabolic complications (bottom), the heart more effectively converts glucose to energy. (W. TODD CADE)

(Medical Xpress) -- People with HIV often develop blood sugar and lipid problems and other metabolic complications that increase the risk of heart disease. But new research at Washington University School of Medicine in St. Louis shows that the HIV virus and the drugs used to treat it don’t worsen heart metabolism and function in these patients, compared with HIV-negative patients with metabolic complications.

The findings are reported online in the journal Cardiovascular Diabetology.

The researchers say the findings were surprising because metabolic complications like insulin resistance, diabetes and problems with blood lipids — such as cholesterol, triglycerides and fatty acids — have become common as improved therapies enable patients with HIV to live longer. These complications also tend to strike HIV-infected people at a younger age. Scientists have long speculated that these problems are caused either by the virus or the antiretroviral therapies used to prevent the infection from progressing to full-blown AIDS.

The scientists used positron emission tomography (PET) imaging and echocardiography to study the heart in four groups of patients: 23 HIV-positive men with metabolic complications; 15 HIV-positive men without those problems; nine HIV-negative men with metabolic complications; and 22 HIV-negative men without them.

The PET studies measured how well the heart processes glucose, an indicator of how well the heart converts sugar into energy. The echocardiograms measured heart function, in particular the ability of the heart to relax between beats, known as diastolic function.

“We had thought that HIV-positive men with insulin and blood lipid problems would have the worst glucose utilization in the heart and the worst diastolic heart function,” says principal investigator W. Todd Cade, PT, PhD, assistant professor of physical therapy and of medicine. “But instead we found that HIV really didn’t make much difference. Men with these had impaired glucose utilization in the heart and poor diastolic function, regardless of HIV status.”

But the effectiveness of anti-HIV drugs may explain why heart function among HIV-positive men in this study was not worse than that of their HIV-negative counterparts, Cade says.

“We think HIV infection made little difference because the virus was so well controlled in the men we studied,” he says. “They had strong immune systems. If we had looked at patients with impaired immune systems and higher virus levels, we may have seen more heart problems.”

Cade says it’s possible that if a larger study were conducted, researchers may be able to tease out very small differences in heart function between HIV-positive and HIV-negative men.

“Our results suggest that men with metabolic problems should receive treatment, regardless of HIV status,” Cade says. “Whether you have HIV or not, insulin resistance and high blood lipids impair your heart’s ability to process nutrients, which over time can interfere with heart function, but our study showed that having well-controlled infection doesn’t make metabolism and function any worse.”

Explore further: Kids born with HIV growing up well

More information: Cade WT, et al. Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow and oxygen consumption: a cross-sectional analysis. Cardiovascular Diabetology, Dec. 2011. (Epub ahead of print).

Related Stories

Kids born with HIV growing up well

April 21, 2011
(PhysOrg.com) -- Once facing an almost certain death sentence, most children born with HIV are now faring well into adolescence and adulthood, according to a newly published study co-authored by Tulane infectious diseases ...

Understanding the link between HIV and dementia

June 29, 2011
(Medical Xpress) -- HIV can hide out in the brain, protected from the immune system and antiviral drugs, Dr. Lachlan Gray and his colleagues at Monash University and the Burnet Institute have found.

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.